Blog
RSS FeedPosted by Michael Wonder on 14 Oct 2020
Bayer submits supplemental new drug application to the FDA for intrauterine device Mirena (levonorgestrel releasing intrauterine system) 52 mg
14 October 2020 - Application seeks to extend duration of use up to seven years for Mirena. ...
Posted by Michael Wonder on 14 Oct 2020
CTI BioPharma initiates rolling submission of new drug application for pacritinib in myelofibrosis patients with severe thrombocytopenia
13 October 2020 - Completion of submission expected in first quarter 2021. ...
Posted by Michael Wonder on 13 Oct 2020
Moderna announces initiation of rolling submission to Health Canada for mRNA vaccine against COVID-19 (mRNA-1273)
13 October 2020 - Confirmation underscores Moderna’s commitment to make its vaccine available in Canada. ...
Posted by Michael Wonder on 13 Oct 2020
Roche to launch laboratory SARS-CoV-2 antigen test to support high-volume testing of suspected COVID-19 patients
13 October 2020 - The Elecsys SARS-CoV-2 Antigen test is an automated laboratory assay intended as an aid in the diagnosis ...
Posted by Michael Wonder on 13 Oct 2020
PMV Pharma granted FDA fast track designation of PC14586 for the treatment of advanced cancer patients that have tumours with a p53 Y220C mutation
13 October 2020 - PMV Pharmaceuticals today announced that the U.S. FDA has granted fast track designation to its lead product ...
Posted by Michael Wonder on 13 Oct 2020
COVID-19 vaccines are chance at salvation, financial and beyond, for drug makers
13 October 2020 - Big profits beckon for pharmaceutical companies, which are already using their work on vaccines to fight efforts ...
Posted by Michael Wonder on 13 Oct 2020
Oxular receives rare paediatric disease and orphan drug designations for retinoblastoma treatment
12 October 2020 - Provides furthered momentum for OXU-003 development programme. ...
Posted by Michael Wonder on 12 Oct 2020
Inventiva receives FDA breakthrough therapy designation for lead drug candidate lanifibranor in NASH
12 October 2020 - Inventiva today announced that the U.S. FDA has granted breakthrough therapy designation to lanifibranor, the Company’s lead ...
Posted by Michael Wonder on 12 Oct 2020
EMA publishes agenda for 12-15 October CHMP meeting
12 October 2020 - The EMA has published a draft agenda for this week's CHMP meeting. ...
Posted by Michael Wonder on 12 Oct 2020
Efficacy trials cost more, take longer for biosimilars than originators
11 October 2020 - Average clinical efficacy testing cost millions of dollars more for Phase 3 biosimilar studies than for ...
Posted by Michael Wonder on 12 Oct 2020
Pfizer trying to defuse critics amid push for vaccine before Election Day
10 October 2020 - The company behind President Donald Trump’s last hope for a vaccine by Election Day has quietly ...
Posted by Michael Wonder on 12 Oct 2020
Alexion receives FDA approval for new advanced formulation of Ultomiris (ravulizumab-cwvz) with significantly reduced infusion time
12 October 2020 - New 100 mg/mL formulation will reduce infusion time by approximately 60 percent, lessening the burden on patients. ...
Posted by Michael Wonder on 12 Oct 2020
TGA grants provisional determination for COVID-19 vaccine
9 October 2020 - The Therapeutic Goods Administration has granted a provisional determination to AstraZeneca in relation to its COVID-19 ...
Posted by Michael Wonder on 11 Oct 2020
Axovant Gene Therapies receives rare paediatric disease designation for AXO-AAV-GM1 for GM1 gangliosidosis
9 October 2020 - Company on-track to report data from on-going Phase 1/2 clinical study in Q4 2020. ...
Posted by Michael Wonder on 11 Oct 2020
Moderna vows to not enforce COVID-19 vaccine patents during pandemic
8 October 2020 - The company is also willing to license the technology behind its experimental coronavirus vaccine. ...